Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced it advanced to a new expansion arm of its Phase 1b/2 clinical trial of ...

NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections ...

This expansion will evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity.

Indaptus began a new expansion phase of its Decoy20 trial, combining it with BeiGene’s tislelizumab to assess safety and anti-tumor activity The company expects its cash reserves to fund ...

The latest results from the weekly dosing cohort show that Decoy20 is generally well-tolerated and has led to immune cell trafficking, a key process in effective anticancer immune response.

This expansion will evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity.

Initial data indicate that Decoy20 at the 30 million cell dose was generally well-tolerated, with a favorable safety profile and promising early signs of clinical benefit, including some patients ...

NEW YORK - Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical-stage biotechnology company with a market capitalization of $11.1 million, has shared new pharmacodynamic findings from its ongoing ...